PE20212199A1 - Sintesis de 4-amino-5-metil-1h-piridin-2(1h)-on (compuesto intermedio para la sintesis del antagonista finerenona de mr) a partir de 2-cloro-5-metil-4-nitro-piridina-1-oxido usando el compuesto intermedio 2-cloro-5-metil-4-piridinamina - Google Patents

Sintesis de 4-amino-5-metil-1h-piridin-2(1h)-on (compuesto intermedio para la sintesis del antagonista finerenona de mr) a partir de 2-cloro-5-metil-4-nitro-piridina-1-oxido usando el compuesto intermedio 2-cloro-5-metil-4-piridinamina

Info

Publication number
PE20212199A1
PE20212199A1 PE2021001422A PE2021001422A PE20212199A1 PE 20212199 A1 PE20212199 A1 PE 20212199A1 PE 2021001422 A PE2021001422 A PE 2021001422A PE 2021001422 A PE2021001422 A PE 2021001422A PE 20212199 A1 PE20212199 A1 PE 20212199A1
Authority
PE
Peru
Prior art keywords
methyl
chloro
synthesis
intermediate compound
amino
Prior art date
Application number
PE2021001422A
Other languages
English (en)
Inventor
Johannes Platzek
Kai Lovis
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of PE20212199A1 publication Critical patent/PE20212199A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION DEL INTERMEDIO 4-AMINO-5-METILPIRIDONA DE FORMULA (I) QUE COMPRENDE HACER REACCIONAR EL COMPUESTO 2-CLORO-5-METILPIRIDIN-4-AMINO DE FORMULA (2) EN AUTOCLAVE CON KOH EN PRESENCIA DE METANOL A UNA TEMPERATURA EN EL RANGO DE 160 °C A 200 °C. DICHO COMPUESTO DE FORMULA (I) ES UN INTERMEDIO PARA LA PREPARACION DE FINERENONA QUE ES UN ANTAGONISTA NO ESTEROIDE DEL RECEPTOR MINERALOCORTICOIDE QUE ES UTIL EN EL TRATAMIENTO DE INSUFICIENCIA CARDIACA Y NEFROPATIA DIABETICA.
PE2021001422A 2019-03-05 2020-02-28 Sintesis de 4-amino-5-metil-1h-piridin-2(1h)-on (compuesto intermedio para la sintesis del antagonista finerenona de mr) a partir de 2-cloro-5-metil-4-nitro-piridina-1-oxido usando el compuesto intermedio 2-cloro-5-metil-4-piridinamina PE20212199A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19160904 2019-03-05
PCT/EP2020/055292 WO2020178175A1 (de) 2019-03-05 2020-02-28 Synthese von 4-amino-5-methyl-1h-pyridin-2(1h)-on (zwischenverbindung der synthese des mr antagonisten finerenone) aus 2-chloro-5-methyl-4-nitro-pyridine-1-oxid über die zwischenverbindung 2-chloro-5-methyl-4-pyridinamin

Publications (1)

Publication Number Publication Date
PE20212199A1 true PE20212199A1 (es) 2021-11-16

Family

ID=65991501

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001422A PE20212199A1 (es) 2019-03-05 2020-02-28 Sintesis de 4-amino-5-metil-1h-piridin-2(1h)-on (compuesto intermedio para la sintesis del antagonista finerenona de mr) a partir de 2-cloro-5-metil-4-nitro-piridina-1-oxido usando el compuesto intermedio 2-cloro-5-metil-4-piridinamina

Country Status (16)

Country Link
US (1) US20220153699A1 (es)
EP (1) EP3935045A1 (es)
JP (1) JP2022523986A (es)
KR (1) KR20210135238A (es)
CN (1) CN113474332A (es)
AU (1) AU2020230965A1 (es)
BR (1) BR112021014815A2 (es)
CA (1) CA3132399A1 (es)
CL (1) CL2021002316A1 (es)
CO (1) CO2021011553A2 (es)
IL (1) IL285937A (es)
JO (1) JOP20210242A1 (es)
MX (1) MX2021010612A (es)
PE (1) PE20212199A1 (es)
SG (1) SG11202109546RA (es)
WO (1) WO2020178175A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114656400A (zh) * 2022-04-26 2022-06-24 浙江科聚生物医药有限公司 一种非奈利酮关键中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1311185A (zh) * 2000-03-03 2001-09-05 山东新华制药股份有限公司 4－氨基吡啶及衍生物的制备方法
US7462612B2 (en) 2004-03-26 2008-12-09 Vertex Pharmaceuticals Incorporated Pyridine inhibitors of ERK2 and uses thereof
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
CN103193704B (zh) * 2013-04-12 2016-03-09 四川铂瑞生物医药有限公司 2-羟基-4-氨基-5-甲基吡啶杂环化合物
HUE051350T2 (hu) 2014-08-01 2021-03-01 Bayer Pharma AG Eljárás (4S)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftridin-3-karboxamid elõállítására és tisztítására gyógyászati hatóanyagként való alkalmazása céljából

Also Published As

Publication number Publication date
AU2020230965A1 (en) 2021-09-23
WO2020178175A1 (de) 2020-09-10
CL2021002316A1 (es) 2022-04-08
CO2021011553A2 (es) 2021-09-20
IL285937A (en) 2021-10-31
EP3935045A1 (de) 2022-01-12
JP2022523986A (ja) 2022-04-27
SG11202109546RA (en) 2021-09-29
JOP20210242A1 (ar) 2023-01-30
CA3132399A1 (en) 2020-09-10
BR112021014815A2 (pt) 2021-09-28
CN113474332A (zh) 2021-10-01
MX2021010612A (es) 2021-09-28
US20220153699A1 (en) 2022-05-19
KR20210135238A (ko) 2021-11-12

Similar Documents

Publication Publication Date Title
CO2021009240A2 (es) Compuestos moduladores de fxr (nr1h4)
MA38540B1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
AR064777A1 (es) Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
ZA202306748B (en) Glp-1r receptor agonist compound and use thereof
AR065877A1 (es) Antagonoistas del receptor opioide periferico y usos de los mismos
CR11393A (es) Agonistas novedosos de los receptores de glucocorticoides
NI201300023A (es) Anticuerpos para el receptor 3 del factor de crecimiento epidérmico (her 3)
UY32379A (es) Derivados de n-heteroarilo sulfonammida sustituidos, sales, solvatos o tautómero farmacéuticamente aceptables, procesos de preparación, intermedios, composicones conteniéndolos y aplicaciones.
PE20230156A1 (es) Sal de acido clorhidrico de (r)-4-(3-((s)-1-(4-amino-3-metil-1h pirazolo[3,4-d]pirimidin-1-il)etil)-5-cloro-2-etoxi-6-fluorofenil)pirrolidin-2-ona
CY1119452T1 (el) Μια μεθοδος παρασκευης 2-αιθοξυ-1-(2'-((υδροξυamino) ιμινομεθυλο) διφαινυλ-4-υλο) μεθυλο)-1η- βενζο (d) ιμιδαζολο-7-καρβοξυλικο οξυ και τους εστερες αυτου
ECSP109922A (es) Compuestos de pirazol y su uso como inhibidores raf
AR064165A1 (es) Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
ATE459352T1 (de) Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe
PE20212199A1 (es) Sintesis de 4-amino-5-metil-1h-piridin-2(1h)-on (compuesto intermedio para la sintesis del antagonista finerenona de mr) a partir de 2-cloro-5-metil-4-nitro-piridina-1-oxido usando el compuesto intermedio 2-cloro-5-metil-4-piridinamina
CU20220064A7 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
ECSP099565A (es) Compuesto de 2-amino pirimidina
CL2009001414A1 (es) Procedimiento de sintesis de 7,8-dimetoxi-1,3-dihidro-2h-3-benzazepin-2-ona sin aislacion de compuestos intermediarios; util para la sintesis de ivabradina.
CU20220065A7 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
CO6620038A2 (es) Compuestos de adenosina y su uso
ECSP23051657A (es) Nuevos compuestos como inhibidor dual del receptor de andrógenos y de la fosfodiesterasa
TW426672B (en) Novel carboxylic acid derivatives, their preparation and use
PE20081497A1 (es) Nuevo procedimiento para la preparacion de 4-4'-(1-metil-1,2-etandiil)-bis-(2,6-piperazindiona)
CL2022000892A1 (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4